Core Viewpoint - Jinbo Biological is not merely a cosmetic enterprise but a pioneer in the field of human-derived collagen, with significant technological advancements and market potential in the medical sector [1][12]. Group 1: Company Overview - Jinbo Biological (832982.BJ) announced a deep collaboration with Zhong Shanshan's Yangshengtang, involving a total investment of up to 34 billion yuan, which includes a 20 billion yuan capital increase and a 14.03 billion yuan share transfer [2][3]. - The company holds a 100% market share in the category of three types of medical devices related to collagen [2]. - The founder, Yang Xia, has transformed Jinbo Biological into a leader in the recombinant human collagen market, overcoming significant technical challenges [3][11]. Group 2: Technological Advancements - The company successfully developed the first recombinant type III collagen product in 2014, after years of research and overcoming various technical hurdles [5][6]. - In 2018, Jinbo Biological achieved a breakthrough by synthesizing a unique A-type recombinant type III human collagen with a specific triple helix structure, marking a significant advancement in the field [7][8]. - The company received regulatory approval for its recombinant type III human-derived collagen freeze-dried fiber product in June 2021, establishing it as a leader in the new biological materials sector [8][9]. Group 3: Financial Performance - Jinbo Biological's revenue surged from 233 million yuan in 2021 to 780 million yuan in 2023, reflecting a compound annual growth rate of 82.8% [9][12]. - Net profit increased dramatically from 57.39 million yuan to 732 million yuan, with a cumulative growth exceeding 500% [9]. - The gross margin improved from 82.29% in 2021 to 92.02% in 2023, surpassing that of major competitors [9]. Group 4: Market Position and Future Outlook - The company is positioned to enter the international beauty supply chain, including partnerships with major brands like L'Oréal, enhancing its market reach [9][10]. - Jinbo Biological aims to expand its product line to cover various medical applications, including oral, orthopedic, and gynecological fields, focusing on human tissue repair solutions [11][12]. - The market for recombinant collagen in China is projected to reach 58.6 billion yuan by 2025 and exceed 200 billion yuan by 2030, indicating a significant growth opportunity despite increasing competition [12].
“锦波不是医美企业”，山西女首富计划减持14亿